Extensive-stage (ES) SCLC (stages III and IV), often the stage at which patients present, has a much worse prognosis and is treated with a combination of platinum-based chemotherapy with or without immunotherapy (PDL1 inhibition). This evidence concerns the gene CD274 and small cell lung carcinoma.